Trial Profile

The REBORN Phase II study of untreated ES-SCLC with irinotecan + cisplatin (IP) plus durvalumab

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Irinotecan (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms REBORN

Most Recent Events

03 Sep 2025 New trial record
01 Aug 2025 Primary endpoint has not been met. (Progression-free survival (PFS) rate)
01 Aug 2025 Results of study evaluating Irinotecan + Cisplatin (IP) plus Durvalumab in untreated extensive stage small cell lung cancer patients were published in the Lung Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com